Lionco Pharm Grp Co Ltd Total Assets
Lionco Pharm Grp Co Ltd total assets. Based on the latest financial reports, Lionco Pharm Grp Co Ltd (603669) holds total assets worth CN¥1.12 Billion CNY (≈ $164.48 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Lionco Pharm Grp Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Lionco Pharm Grp Co Ltd (2011–2025)
Total assets of Lionco Pharm Grp Co Ltd from 2011 to 2025. This chart illustrates how Lionco Pharm Grp Co Ltd's total assets have evolved over time, based on quarterly financial data. See Lionco Pharm Grp Co Ltd stock price for real-time trading data and today's change.
Lionco Pharm Grp Co Ltd - Asset Composition Analysis
Lionco Pharm Grp Co Ltd Total Assets Breakdown (December 2025)
Lionco Pharm Grp Co Ltd total assets breakdown as of December 2025. Lionco Pharm Grp Co Ltd's total assets of CN¥1.12 Billion consist of 47.5% current assets and 52.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.1% |
| Accounts Receivable | CN¥256.11 Million | 23.1% |
| Inventory | CN¥84.03 Million | 7.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥93.61 Million | 8.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Lionco Pharm Grp Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Lionco Pharm Grp Co Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lionco Pharm Grp Co Ltd's current assets represent 47.5% of total assets in 2025, a decrease from 56.0% in 2011.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, down from 19.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 23.1% of total assets.
Lionco Pharm Grp Co Ltd Competitors by Total Assets
Key competitors of Lionco Pharm Grp Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Lionco Pharm Grp Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.22 | 2.86 | 2.41 |
| Quick Ratio | 1.05 | 2.62 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥98.96 Million | CN¥372.52 Million | CN¥1.18 Billion |
Lionco Pharm Grp Co Ltd - Advanced Valuation Insights
This section examines the relationship between Lionco Pharm Grp Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.69 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -11.8% |
| Total Assets | CN¥1.11 Billion |
| Market Capitalization | $558.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lionco Pharm Grp Co Ltd's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lionco Pharm Grp Co Ltd's assets decreased by 11.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lionco Pharm Grp Co Ltd (2011–2025)
The table below shows the annual total assets of Lionco Pharm Grp Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.11 Billion ≈ $161.96 Million |
-11.83% |
| 2024-12-31 | CN¥1.26 Billion ≈ $183.69 Million |
-22.73% |
| 2023-12-31 | CN¥1.62 Billion ≈ $237.72 Million |
-12.44% |
| 2022-12-31 | CN¥1.86 Billion ≈ $271.51 Million |
-26.21% |
| 2021-12-31 | CN¥2.51 Billion ≈ $367.93 Million |
-7.43% |
| 2020-12-31 | CN¥2.72 Billion ≈ $397.47 Million |
+41.95% |
| 2019-12-31 | CN¥1.91 Billion ≈ $280.00 Million |
-7.47% |
| 2018-12-31 | CN¥2.07 Billion ≈ $302.60 Million |
+25.20% |
| 2017-12-31 | CN¥1.65 Billion ≈ $241.69 Million |
+22.89% |
| 2016-12-31 | CN¥1.34 Billion ≈ $196.67 Million |
+0.04% |
| 2015-12-31 | CN¥1.34 Billion ≈ $196.60 Million |
+139.98% |
| 2014-12-31 | CN¥559.83 Million ≈ $81.92 Million |
-3.83% |
| 2013-12-31 | CN¥582.12 Million ≈ $85.18 Million |
+59.53% |
| 2012-12-31 | CN¥364.89 Million ≈ $53.39 Million |
+49.31% |
| 2011-12-31 | CN¥244.38 Million ≈ $35.76 Million |
-- |
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Phar… Read more